Clinical Services & Research

Clinical Services

The Ottawa Blood Disease Centre provides care for patients with blood disorders within 3 major categories:

The Ottawa Blood Disease Centre treats patients from all over the Champlain LHIN. Annually, this includes:

  • Over 30,000 outpatient visits
  • Over 2,000 inpatient stays
  • Over 100 bone marrow transplants
  • Over 1,000 telemedicine visits

In early 2013, the Thrombosis clinic moved from the Civic into our new outpatient space, and consolidated all of our benign Hematology clinics from across the city to Module H at the General Campus. These state of the art and brand new ultrasound, lab and clinic facilities will help us to better serve our patients.


Our physicians and staff are devoted to carrying out practice-changing research. We are continually involved in important clinical studies, and our physician/scientists are world-renowned experts in their fields. Our research is conducted through the research arm of The Ottawa Hospital: the Ottawa Hospital Research Institute (OHRI).


Our Division consistently publishes over 100 peer-reviewed articles per year. Highlights of our recent high impact papers include:


Each year,  our investigators are granted millions of dollars to advance life-changing research in the area of blood disease. Highlights of recent grants include:

  • Patient-Centered Outcomes Research Institute: $19,667,813. Ortel T, Castellucci L et al.  Warfarin versus Direct Oral Anticoagulants for Secondary Prevention of Recurrent Venous Thromboembolism: A Randomized Comparative Effectiveness Trial.

  • BioCanRX: $5,500,000. Atkins H, Auer R, Bell J, Diallo J-S, Fergusson D, Kekre N. Capacity building for CAR-T cell therapies in Canada; Infected Cell Vaccines in the Treatment of Acute Leukemia.

  • CIHR: $1,231,650. Castellucci L, Rodger M, Bates S, De Wit K, Kahn S, Kearon C, Kovacs M, Le Gal G, Shivakumar S, Solymoss S, Thavorn K. Blood clots: Comparing new blood thinners to prevent venous thromboembolism.

  • CIHR: $371,026. Fergusson D, ChassĂ© M, Tinmouth A, Acker J, English S, Forster A, Shehata N, Thavorn K, Wilson K. Blood transfusions: Is male donor blood better for recipients than female donor blood?

  • CIHR: $407,356.  Ito C, Perkins, TJ, Sabloff M, Stanford, WL. The role of PCL2/PRC2 in hematopoietic stem cells and leukemia.

  • CIHR: >$5,000,000.  Kahn SR, Rodger MA et al. CanVECTOR (Canadian Venous Thromboembolism Clinical Trials and Outcomes Research) Network.

  • CIHR: $187,878. Sheppard D, Tay J, Tinmouth A, Allan DS, Beattie SM, Bredeson C, Fergusson DA, Sabloff M, Thavorn K. Platelet Transfusions in Hematopoietic Stem Cell Transplantation - The PATH Study.

  • CIHR: $424,298.  Rodger MA, Fergusson DA, Gandara E, Kahn SR, Kearon C, Kovacs MJ, Le Gal G, Ramsay TO, Shivakumar SP, Tagalakis V, Thavom K. StAtins for Venous Even Reduction in Patients with Venous Thromboembolism (SAVER). Top ranking in the 2016 CIHR project competition!

  • Heart & Stroke Foundation: $255,538.  Le Gal G, Anderson D, de Wit K, Kahn S, Kearon C, Ramsay T, Rodger MA, Righini M, Shivakumar S, Wells P. Age-adjusted D-dimer cutoff levels to rule out deep vein thrombosis (The ADJUST-DVT Study).

 Honours & Awards

  • Harold Atkins received the Dr. Michel ChrĂ©tien Researcher of the Year Award for his MS breakthrough research.  This is the third year in a row one of our division physicians has won this prestigious award (2016: Dr. Marc Carrier; 2015: Dr. Marc Rodger).

  • Elianna Saidenberg received the Educator Award in Communicator Competency for “communicating clearly and effectively even in the face of adversity.”

  • Dr. Marc Carrier has been recognized as one of two Ottawa research papers on New England Journal of Medicine’s top 12 list in 2015.  Dr. Carrier found that contrary to expectations, CT scanning does not improve cancer detection in people with unexplained blood clots. According to the journal’s editor, papers chosen for this list represent “the cream of the crop, the dozen studies from 2015 that we think will have the biggest influence on medicine.” His paper also won the Canadian Hematology Society’s Paper of the Year award.